Psychotropic target discovery and subsequent development play important roles in psychotropic drug development. In addition to small molecules belonging to major categories, such as monoamine transporters antagonists, hypothalamic-pituitary-adrenal axis antagonists, and glutamate receptors regulators, there are also many other inhibitors and agonists arousing great interest because of their huge potential in psychotropic drug development. As an industry-leading CRO company, Creative Biolabs provides a full range of target development services to meet global researchers’ detailed requirements.
It is now universally accepted that the appropriate functioning of cellular histone acetylation machinery could be one of the key mechanisms guiding neuronal plasticity, learning, and memory. Thus, targeting to restore histone acetylation homeostasis holds immense promise in the context of neuropsychiatric diseases and related cognitive impairments. The use of HDACs inhibitors as neuroprotective agents may open up a whole new field of application for inhibitors.
Numerous clinical and preclinical findings suggest that disruptions in central nicotinic cholinergic transmission may be associated with the symptoms observed in individuals with schizophrenia. There is a significantly higher incidence of cigarette smoking among individuals with schizophrenia relative to the general population or in individuals with other psychiatric disorders. Smoking behavior in schizophrenia is also reported to be independent of antipsychotic treatment and frequently observed prior to the initiation of antipsychotic therapies. While the underlying causes for the higher rates of smoking in schizophrenia remain unclear, acute nicotine exposure has been shown to improve cognition, particularly in the domains of attention and vigilance, in animals, healthy volunteers, and in smoking and non-smoking schizophrenic patients.
GSK3 has a pervasive influence on neuronal function, affecting the structure, remodeling, gene expression, survival, and many other aspects of cellular operations. Therefore, the activity of GSK3 is tightly controlled in a substrate-specific manner to allow modulation of select actions of GSK3 by many signaling pathways that converge upon it. As would be expected of such a multi-functional enzyme, recent studies have found that the activities of several neurotransmitter systems regulate GSK3 in the brain in a receptor subtype-selective manner. In addition, mounting evidence supports that abnormally regulated GSK3 is associated with mood disorders and possibly schizophrenia. Thus, GSK3 and its signaling partners, both upstream and downstream of GSK3, provide potential targets for new therapeutic agents.
Calcium channel blocking agents (CCBs) comprise a diverse group of medications most frequently used to treat cardiovascular disorders. These agents have different structures and spectra of activity, but they share antagonism of influx through ion-specific channels of calcium ions into cells from the extracellular space. In view of their ability to alter intracellular dynamics in hyperactive cells and their relative tolerability, interest in these medications has recently extended to psychiatric disorders in which hyperactivity of neuronal and other cellular systems is a hallmark. Evidence of derangement of intracellular calcium ion dynamics, as well as a dearth of effective and well-tolerated treatments, has made bipolar disorder become the psychiatric disorder of greatest interest in studies of potential applications of CCBs in psychiatry.
Multiple lines of evidence suggest that alterations in central muscarinic cholinergic neurotransmission are involved in the underlying pathophysiology of schizophrenia. Early validation came from extensive preclinical and clinical studies with non-selective muscarinic acetylcholine receptors (mAChRs) ligands. Non-selective mAChR antagonists robustly impaired multiple cognitive functions and executive tasks, whereas direct- and indirect-acting mAChR agonists enhanced aspects of normal cognition and/or reversed cognitive impairments induced by mAChR antagonists or cholinergic circuit lesions. Moreover, mAChR antagonists induced psychotic-like symptoms and cognitive impairments in healthy subjects and/or exacerbated existing positive and cognitive symptomatology in schizophrenic patients.
Services at Creative Biolabs
Committed to psychotropic drug development for years, Creative Biolabs has established a comprehensive technology platform and a mature development system. With excellent hardware conditions and professional scientists specialized in psychiatric disorders, we are capable of providing high-quality target development services to global researchers. We aim to accelerate industry development through our professional services. Our services cover every step during the process of drug development and both stand-alone services as well as integrated projects are welcomed.
Why Us?
-
One-stop services
-
Ph.D. level expert team
-
Efficient and cost-effective
-
Hundreds of customer-satisfied projects
-
The high degree of recognition from customers
-
Good industry reputation
With proven expertise in psychiatric disorder and relative drug development, Creative Biolabs offers a variety of potential psychotropic target development services. If you have any questions, please feel free to contact us for more information.
For Research Use Only.
